Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study

Introduction: Evidence on the long-term durability of glycemic control beyond the first year of automated insulin delivery therapy remains limited, particularly in large multicenter pediatric cohorts. The present study aimed to evaluate long-term effectiveness and identify determinants of sustained optimal outcomes over 3 years of MiniMed™ 780G use in youth with type 1 diabetes (T1D). Materials and Methods: In this longitudinal, multicenter, real-world study, 359 youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers were followed for 3 years after MiniMed 780G initiation. Glucose metrics, insulin delivery parameters, device settings, and engagement indicators were analyzed at 1, 2, and 3 years. Longitudinal changes were assessed using linear mixed-effects models. Multivariable logistic regression identified predictors of achieving time in tight range target (TITR ≥ 50%) at 3 years. Results: Median time in range (TIR) remained within international targets but declined modestly from 75% at 1 year to 74% at 3 years ( P = 0.002). The percentage of automatic correction boluses increased over time, whereas user-initiated boluses and carbohydrate entries declined ( P < 0.001). Youth with higher TIR at 1 year showed a progressive reduction in TIR and greater increase in automated corrections (time × group interaction P < 0.001). At 3 years, higher SmartGuard use (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 1.03–1.23; P = 0.007), optimal system settings (OR: 3.21, 95% CI: 1.33–7.77; P = 0.010), and lower automatic correction boluses (OR: 0.84, 95% CI: 0.80–0.89; P < 0.001) were independently associated with achieving TITR ≥50%. Conclusions: MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control, highlighting the need for ongoing education and proactive device optimization.

Authors

Institutions

Publication Details

Journal
Diabetes Technology & Therapeutics
Published
2026-07-17
DOI
https://doi.org/10.1177/15209156261469663
Primary Topic
Diabetes Management and Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study

Giulia Pezzino, Barbara Felappi, Giuseppina Salzano, Nicola Minuto et al.
Diabetes Technology & Therapeutics
Diabetes Management and Research
article

Three-Year Durability of Automated Insulin Delivery Therapy in Children and Adolescents with Type 1 Diabetes: A Multicenter Real-World Study

Giulia Pezzino, Barbara Felappi, Giuseppina Salzano, Nicola Minuto, Claudia Arnaldi, Giulio Maltoni, S Passanisi, Bruno Bombaci, Andrea Rigamonti, Rosalia Roppolo, Maurizio Delvecchio, Angela Zanfardino, Eulalia Catamo, Petra Reinstadler, R Bonfanti, G V Zuccotti, Donatella Lo Presti, Fortunato Lombardo, C Maffeis, Claudia Piona, Gianluca Tornese, Enza Mozzillo, Chiara Mameli, Marta Bassi, ISPED Diabetes Group Study Collaborators, Mila A. Kalapurackal
article en

Abstract

Introduction: Evidence on the long-term durability of glycemic control beyond the first year of automated insulin delivery therapy remains limited, particularly in large multicenter pediatric cohorts. The present study aimed to evaluate long-term effectiveness and identify determinants of sustained optimal outcomes over 3 years of MiniMed™ 780G use in youth with type 1 diabetes (T1D). Materials and Methods: In this longitudinal, multicenter, real-world study, 359 youth with T1D (median age 12.2 years, 50.9% female) from 20 Italian pediatric diabetes centers were followed for 3 years after MiniMed 780G initiation. Glucose metrics, insulin delivery parameters, device settings, and engagement indicators were analyzed at 1, 2, and 3 years. Longitudinal changes were assessed using linear mixed-effects models. Multivariable logistic regression identified predictors of achieving time in tight range target (TITR ≥ 50%) at 3 years. Results: Median time in range (TIR) remained within international targets but declined modestly from 75% at 1 year to 74% at 3 years ( P = 0.002). The percentage of automatic correction boluses increased over time, whereas user-initiated boluses and carbohydrate entries declined ( P < 0.001). Youth with higher TIR at 1 year showed a progressive reduction in TIR and greater increase in automated corrections (time × group interaction P < 0.001). At 3 years, higher SmartGuard use (odds ratio [OR]: 1.13, 95% confidence interval [CI]: 1.03–1.23; P = 0.007), optimal system settings (OR: 3.21, 95% CI: 1.33–7.77; P = 0.010), and lower automatic correction boluses (OR: 0.84, 95% CI: 0.80–0.89; P < 0.001) were independently associated with achieving TITR ≥50%. Conclusions: MiniMed 780G provides sustained glycemic control over 3 years. However, progressive reliance on automated corrections and reduced user engagement may attenuate tight glycemic control, highlighting the need for ongoing education and proactive device optimization.

Diabetes Technology & Therapeutics
University of Messina (IT), University of Verona (IT), University of Trieste (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), University of L'Aquila (IT), IRCCS Materno Infantile Burlo Garofolo (IT), Ospedale di Bolzano (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Ospedale Garibaldi (IT), Azienda Sanitaria Locale Viterbo (IT), Istituto Ortopedico Gaetano Pini (IT), Azienda USL di Bologna (IT), University of Campania "Luigi Vanvitelli" (IT), Policlinico Universitario di Catania (IT), Ospedale Pediatrico Giovanni XXIII (IT), Azienda di Rilievo Nazionale ed Alta Specializzazione (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), ASST Fatebenefratelli Sacco (IT), University of Genoa (IT)
Openalex Percentile: Top 8%
Diabetes Management and Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.